Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

JAGX vs MCK vs CAH vs HSIC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
JAGX
Jaguar Health, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$199K
5Y Perf.-100.0%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+374.1%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$43.59B
5Y Perf.+238.7%
HSIC
Henry Schein, Inc.

Medical - Distribution

HealthcareNASDAQ • US
Market Cap$8.09B
5Y Perf.+16.1%

JAGX vs MCK vs CAH vs HSIC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
JAGX logoJAGX
MCK logoMCK
CAH logoCAH
HSIC logoHSIC
IndustryBiotechnologyMedical - DistributionMedical - DistributionMedical - Distribution
Market Cap$199K$92.15B$43.59B$8.09B
Revenue (TTM)$12M$403.43B$250.55B$13.18B
Net Income (TTM)$-54M$4.76B$1.56B$398M
Gross Margin67.2%3.6%3.7%29.1%
Operating Margin-398.8%1.5%0.9%5.8%
Forward P/E19.3x17.9x13.3x
Total Debt$44M$7.39B$9.35B$3.69B
Cash & Equiv.$968K$5.69B$3.87B$156M

JAGX vs MCK vs CAH vs HSICLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

JAGX
MCK
CAH
HSIC
StockMay 20May 26Return
Jaguar Health, Inc. (JAGX)1000.0-100.0%
McKesson Corporation (MCK)100474.1+374.1%
Cardinal Health, In… (CAH)100338.7+238.7%
Henry Schein, Inc. (HSIC)100116.1+16.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: JAGX vs MCK vs CAH vs HSIC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK and CAH are tied at the top with 3 categories each — the right choice depends on your priorities. Cardinal Health, Inc. is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. HSIC also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
JAGX
Jaguar Health, Inc.
The Secondary Option

JAGX lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
MCK
McKesson Corporation
The Growth Play

MCK carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
  • 348.1% 10Y total return vs CAH's 160.8%
  • PEG 0.49 vs HSIC's 4.21
  • 16.2% revenue growth vs CAH's -1.9%
Best for: growth exposure and long-term compounding
CAH
Cardinal Health, Inc.
The Income Pick

CAH is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.

  • Dividend streak 20 yrs, beta 0.03, yield 1.1%
  • Lower volatility, beta 0.03, current ratio 0.94x
  • Beta 0.03, yield 1.1%, current ratio 0.94x
  • Beta 0.03 vs JAGX's 2.72
Best for: income & stability and sleep-well-at-night
HSIC
Henry Schein, Inc.
The Quality Compounder

HSIC is the clearest fit if your priority is quality.

  • 3.0% margin vs JAGX's -465.4%
Best for: quality
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK16.2% revenue growth vs CAH's -1.9%
ValueMCK logoMCKBetter valuation composite
Quality / MarginsHSIC logoHSIC3.0% margin vs JAGX's -465.4%
Stability / SafetyCAH logoCAHBeta 0.03 vs JAGX's 2.72
DividendsCAH logoCAH1.1% yield, 20-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Momentum (1Y)CAH logoCAH+22.0% vs JAGX's -99.2%
Efficiency (ROA)MCK logoMCK5.7% ROA vs JAGX's -114.3%, ROIC 5.4% vs -116.8%

JAGX vs MCK vs CAH vs HSIC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

JAGXJaguar Health, Inc.
FY 2025
Mytesi
98.2%$11M
License
1.5%$172,000
Neonorm
0.3%$35,000
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B
HSICHenry Schein, Inc.
FY 2018
Healthcare Distribution
96.1%$12.7B
Technology
3.9%$509M

JAGX vs MCK vs CAH vs HSIC — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCAHLAGGINGHSIC

Income & Cash Flow (Last 12 Months)

HSIC leads this category, winning 3 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 35047.3x JAGX's $12M. HSIC is the more profitable business, keeping 3.0% of every revenue dollar as net income compared to JAGX's -4.7%. On growth, CAH holds the edge at +11.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricJAGX logoJAGXJaguar Health, In…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …HSIC logoHSICHenry Schein, Inc.
RevenueTrailing 12 months$12M$403.4B$250.5B$13.2B
EBITDAEarnings before interest/tax-$54M$6.8B$3.2B$1.1B
Net IncomeAfter-tax profit-$54M$4.8B$1.6B$398M
Free Cash FlowCash after capex-$24M$6.0B$4.4B$561M
Gross MarginGross profit ÷ Revenue+67.2%+3.6%+3.7%+29.1%
Operating MarginEBIT ÷ Revenue-4.0%+1.5%+0.9%+5.8%
Net MarginNet income ÷ Revenue-4.7%+1.2%+0.6%+3.0%
FCF MarginFCF ÷ Revenue-2.1%+1.5%+1.8%+4.3%
Rev. Growth (YoY)Latest quarter vs prior year-7.8%+6.0%+11.0%+7.7%
EPS Growth (YoY)Latest quarter vs prior year+90.1%+37.0%-19.5%+14.9%
HSIC leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

JAGX leads this category, winning 3 of 6 comparable metrics.

At 21.6x trailing earnings, HSIC trades at a 26% valuation discount to MCK's 29.2x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs HSIC's 6.84x — a lower PEG means you pay less per unit of expected earnings growth.

MetricJAGX logoJAGXJaguar Health, In…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …HSIC logoHSICHenry Schein, Inc.
Market CapShares × price$198,587$92.1B$43.6B$8.1B
Enterprise ValueMkt cap + debt − cash$43M$93.8B$49.1B$11.6B
Trailing P/EPrice ÷ TTM EPS-0.00x29.25x28.72x21.56x
Forward P/EPrice ÷ next-FY EPS est.19.28x17.94x13.26x
PEG RatioP/E ÷ EPS growth rate0.75x6.84x
EV / EBITDAEnterprise value multiple18.74x16.01x10.87x
Price / SalesMarket cap ÷ Revenue0.02x0.26x0.20x0.61x
Price / BookPrice ÷ Book value/share1.79x
Price / FCFMarket cap ÷ FCF0.03x17.63x23.56x14.12x
JAGX leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 8 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $8 for HSIC. On the Piotroski fundamental quality scale (0–9), MCK scores 6/9 vs JAGX's 3/9, reflecting solid financial health.

MetricJAGX logoJAGXJaguar Health, In…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …HSIC logoHSICHenry Schein, Inc.
ROE (TTM)Return on equity+3.0%+8.2%
ROA (TTM)Return on assets-114.3%+5.7%+2.8%+3.6%
ROICReturn on invested capital-116.8%+5.4%+33.8%+7.1%
ROCEReturn on capital employed-2.9%+30.5%+19.2%+9.8%
Piotroski ScoreFundamental quality 0–93664
Debt / EquityFinancial leverage0.77x
Net DebtTotal debt minus cash$43M$1.7B$5.5B$3.5B
Cash & Equiv.Liquid assets$968,000$5.7B$3.9B$156M
Total DebtShort + long-term debt$44M$7.4B$9.3B$3.7B
Interest CoverageEBIT ÷ Interest expense-565.60x33.79x6.38x4.59x
MCK leads this category, winning 5 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

CAH leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $0 for JAGX. Over the past 12 months, CAH leads with a +22.0% total return vs JAGX's -99.2%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.5% vs JAGX's -93.8% — a key indicator of consistent wealth creation.

MetricJAGX logoJAGXJaguar Health, In…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …HSIC logoHSICHenry Schein, Inc.
YTD ReturnYear-to-date-91.5%-8.5%-9.5%-8.2%
1-Year ReturnPast 12 months-99.2%+4.6%+22.0%+5.9%
3-Year ReturnCumulative with dividends-100.0%+106.4%+127.3%-11.7%
5-Year ReturnCumulative with dividends-100.0%+286.9%+235.7%-12.5%
10-Year ReturnCumulative with dividends-100.0%+348.1%+160.8%+5.3%
CAGR (3Y)Annualised 3-year return-93.8%+27.3%+31.5%-4.0%
CAH leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

CAH leads this category, winning 2 of 2 comparable metrics.

CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than JAGX's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CAH currently trades 79.3% from its 52-week high vs JAGX's 0.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricJAGX logoJAGXJaguar Health, In…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …HSIC logoHSICHenry Schein, Inc.
Beta (5Y)Sensitivity to S&P 5002.72x0.04x0.03x0.73x
52-Week HighHighest price in past year$395.85$999.00$233.60$89.29
52-Week LowLowest price in past year$0.71$637.00$137.75$61.95
% of 52W HighCurrent price vs 52-week peak+0.8%+75.3%+79.3%+79.0%
RSI (14)Momentum oscillator 0–10016.716.233.239.1
Avg Volume (50D)Average daily shares traded42K757K1.7M1.2M
CAH leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

CAH leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: MCK as "Buy", CAH as "Buy", HSIC as "Hold". Consensus price targets imply 34.8% upside for CAH (target: $250) vs 22.6% for HSIC (target: $86). For income investors, CAH offers the higher dividend yield at 1.10% vs MCK's 0.36%.

MetricJAGX logoJAGXJaguar Health, In…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …HSIC logoHSICHenry Schein, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyHold
Price TargetConsensus 12-month target$1006.50$249.67$86.43
# AnalystsCovering analysts313332
Dividend YieldAnnual dividend ÷ price+0.4%+1.1%
Dividend StreakConsecutive years of raises17201
Dividend / ShareAnnual DPS$2.69$2.04
Buyback YieldShare repurchases ÷ mkt cap+100.0%+3.4%+1.8%+10.5%
CAH leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

CAH leads in 3 of 6 categories (Total Returns, Risk & Volatility). HSIC leads in 1 (Income & Cash Flow).

Best OverallCardinal Health, Inc. (CAH)Leads 3 of 6 categories
Loading custom metrics...

JAGX vs MCK vs CAH vs HSIC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is JAGX or MCK or CAH or HSIC a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — JAGX or MCK or CAH or HSIC?

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 6x versus McKesson Corporation at 29. 2x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Henry Schein, Inc. 's 4. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — JAGX or MCK or CAH or HSIC?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -100. 0% for Jaguar Health, Inc. (JAGX). Over 10 years, the gap is even starker: MCK returned +348. 1% versus JAGX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — JAGX or MCK or CAH or HSIC?

By beta (market sensitivity over 5 years), Cardinal Health, Inc.

(CAH) is the lower-risk stock at 0. 03β versus Jaguar Health, Inc. 's 2. 72β — meaning JAGX is approximately 7911% more volatile than CAH relative to the S&P 500.

05

Which is growing faster — JAGX or MCK or CAH or HSIC?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to 7. 2% for Henry Schein, Inc.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — JAGX or MCK or CAH or HSIC?

Henry Schein, Inc.

(HSIC) is the more profitable company, earning 3. 0% net margin versus -465. 4% for Jaguar Health, Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HSIC leads at 5. 7% versus -398. 8% for JAGX. At the gross margin level — before operating expenses — JAGX leads at 67. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is JAGX or MCK or CAH or HSIC more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Henry Schein, Inc. 's 4. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 3x forward P/E versus 19. 3x for McKesson Corporation — 6. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAH: 34. 8% to $249. 67.

08

Which pays a better dividend — JAGX or MCK or CAH or HSIC?

In this comparison, CAH (1.

1% yield), MCK (0. 4% yield) pay a dividend. JAGX, HSIC do not pay a meaningful dividend and should not be held primarily for income.

09

Is JAGX or MCK or CAH or HSIC better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Jaguar Health, Inc. (JAGX) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAH: +160. 8%, JAGX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between JAGX and MCK and CAH and HSIC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: JAGX is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock; HSIC is a small-cap quality compounder stock. CAH pays a dividend while JAGX, MCK, HSIC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

JAGX

Quality Business

  • Sector: Healthcare
  • Market Cap > $20B
  • Gross Margin > 40%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

CAH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

HSIC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 17%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform JAGX and MCK and CAH and HSIC on the metrics below

Revenue Growth>
%
(JAGX: -7.8% · MCK: 6.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.